NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

神經生物標記的全球市場:用途,類型,終端用戶,各地區 - 產業展望,全面性分析,2020年∼2026年的預測

Neurological Biomarkers Market - By Application, By Type, By End-User, And By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 - 2026

出版商 Zion Market Research 商品編碼 956515
出版日期 內容資訊 英文 110 Pages
商品交期: 2-3個工作天內
價格
神經生物標記的全球市場:用途,類型,終端用戶,各地區 - 產業展望,全面性分析,2020年∼2026年的預測 Neurological Biomarkers Market - By Application, By Type, By End-User, And By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 - 2026
出版日期: 2020年08月24日內容資訊: 英文 110 Pages
簡介

全球神經生物標記的市場規模在2019年估算為約63億7,169萬美金。該市場在2020年∼2026年間,預測將以14.5%的年複合成長率增長。

本報告提供全球神經生物標記市場的相關調查,提供市場機會,成長及阻礙因素,用途·類型·終端用戶·各地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 序文

第2章 摘要整理

  • 市場規模(2016-2026)
  • 市場概述

第3章 產業分析

  • 市場動態
  • 市場成長要素
  • 波特的五力分析
  • 市場魅力分析

第4章 競爭情形

  • 企業的市場佔有率分析
  • 策略性開發

第5章 市場分析:各用途

  • 市場概要
  • 阿茲海默症
  • 帕金森氏症
  • 泛自閉症障礙
  • 多發性硬化症
  • 其他

第6章 市場分析:各類型

  • 市場概要
  • 蛋白質體學
  • 基因
  • 成像
  • 代細胞
  • 其他

第7章 市場分析:各終端用戶

  • 市場概要
  • 獨立的臨床診斷中心
  • 醫院研究所
  • 調查機關
  • 其他

第8章 企業簡介

  • QIAGEN
  • Abbott
  • Thermo Fisher Scientific Inc.
  • Myriad RBM
  • Bio-Rad Laboratories, Inc.
  • Athena Diagnostics
  • Acumen Pharmaceuticals
  • AbaStar MDx, Inc.
  • Alseres Pharmaceuticals, Inc.
  • BANYAN BIOMARKERS, INC.
目錄

Title:
Neurological Biomarkers Market - By Application (Alzheimer's Disease, Parkinson's Disease, Autism Spectrum Disorders, Multiple Sclerosis, and Others), By Type (Proteomic, Genomic, Imaging, Metabolomic, and Others), By End-User (Independent Clinical Diagnostic Centers, Hospital Laboratories, Research Organizations, and Others), And By Region - Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 - 2026.

The global Neurological Biomarkers market, which accrued nearly 6,371.69 (USD Million) in 2019, is set to record the CAGR of 14.5% over the period from 2020 to 2026. The report offers assessment and analysis of the Neurological Biomarkers market on a global and regional level. The study offers a comprehensive assessment of the market competition, constraints, sales estimates, opportunities, evolving trends, and industry-validated data. The report offers historical data from 2017 to 2019 along with a forecast from 2020 to 2026 based on revenue (USD Million).

Introduction

Neurological biomarkers are utilized for detecting the persons at the risk of having neurological ailments and some of these biomarkers are used for diagnosing the disorder, determine its progress, and estimate the disease result. In therapeutic surroundings, these biomarkers unleash information related to the effectiveness of the medicine for a particular neurological disorder as well as its side-effects. Citing an instance, uric acid is a key biomarker that helps in detecting the growth of Parkinson ailment and the need for the drug development to inhibit the growth. In addition to this, MRI-based biomarkers help in determining intensity of multiple sclerosis, spinal muscular atrophy, retinal neurodegenerative disorder, and acute ischemic strokes.

Market Growth Dynamics

Technological innovations in genomics, metabolomics, and proteomics are predicted to steer the growth of neurological biomarkers industry over the estimated timeframe. Apparently, large-scale occurrence of the neurological ailments due to stressful & hectic work schedule as well as work-life imbalance will drive the market trends. In addition to this, less proportion of effective diagnostics tools available in emerging countries has resulted in rise in the mortality due to neurological diseases, thereby enhancing the need for neurological biomarkers in these countries.

Furthermore, surge in the neurological disorders like Alzheimer, brain tumors, Parkinson, cerebral stroke, and epilepsy will pave a way for the industry growth over the forecasting years. Apparently, favorable government schemes as well as rise in the investment in neurological diagnostics sector has translated into market demand. Rise in the research activities pertaining to neuroscience and huge funding provided by the government agencies to promote neuro-medicine discoveries will embellish the industry expansion in the coming years.

Asia Pacific Market To Accrue Huge Returns Over 2020-2026

Rise in the occurrence of neurological disorders like Alzheimer and Parkinson among the aging population has generated huge demand for the neurological biomarker, thereby spurring the market growth in the region. Apart from this, rise in the awareness pertaining to neurological diseases and a complete overhaul as well as drastic improvisations witnessed in healthcare infrastructure facilities in the countries like China will magnify the market growth in the Asia Pacific zone. Apart from China, countries like South Korea and India are projected to be the major regional revenue drivers over the next couple of years.

Key players influencing the market growth are Bio-Rad Laboratories, Inc., QIAGEN, Alseres Pharmaceuticals, Inc., Abbott, Thermo Fisher Scientific Inc., Acumen Pharmaceuticals, Myriad RBM, Athena Diagnostics; AbaStar MDx, Inc., and BANYAN BIOMARKERS, INC.

The global neurological biomarkers market is segmented as follows:

By application:

  • Multiple Sclerosis
  • Alzheimer’s Disease
  • Parkinson’s Disease
  • Autism Spectrum Disorders
  • Others

By type:

  • Metabolomic
  • Genomic
  • Proteomic
  • Imaging
  • Others

By end-user:

  • Research Organizations
  • Hospital Laboratories
  • Independent Clinical Diagnostic Centers
  • Others
  • By Region
  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

Table Of Contents

Chapter 1. Preface

  • 1.1. Report Description and Scope
  • 1.2. Research Scope
  • 1.3. Research Methodulogy
    • 1.3.1. Market Research Type
    • 1.3.2. Market Research Methodulogy

Chapter 2. Executive Summary

  • 2.1. Neurulogical Biomarkers Market, 2016–2026(USD Million)
  • 2.2. Neurulogical Biomarkers Market: Snapshot

Chapter 3. Global Neurulogical Biomarkers Market– Industry Analysis

  • 3.1. Neurulogical Biomarkers Market: Market Dynamics
  • 3.2. Market Drivers
    • 3.2.1. Large-scale occurrence of the neurulogical ailments due to stressful & hectic work schedule as well as work-life imbalance will drive the market trends.
    • 3.2.2. Less proportion of effective diagnostics touls available in emerging countries has resulted in rise in the mortality due to neurulogical diseases, thereby enhancing the need for neurulogical biomarkers in these countries.
  • 3.3. Porter’s Five Forces Analysis
  • 3.4. Market Attractiveness Analysis
    • 3.4.1. Market attractiveness analysis By Type
    • 3.4.2. Market attractiveness analysis By Application
    • 3.4.3. Market attractiveness analysis By End-User

Chapter 4. Global Neurulogical Biomarkers Market– Competitive Landscape

  • 4.1. Company market share analysis
    • 4.1.1. Global Neurulogical Biomarkers Market: company market share, 2019
  • 4.2. Strategic development
    • 4.2.1. Acquisitions & mergers
    • 4.2.2. New Product launches
    • 4.2.3. Agreements, partnerships, cullaborations, and joint ventures
    • 4.2.4. Research and development and Regional expansion
    • 4.2.5. Price trend analysis

Chapter 5. Global Neurulogical Biomarkers Market–Application Analysis

  • 5.1. Global Neurulogical Biomarkers Market overview: By Application
    • 5.1.1. Global Neurulogical Biomarkers Market share, By Application ,2019 and 2026
  • 5.2. Alzheimer’s Disease
    • 5.2.1. Global Neurulogical Biomarkers Market by Alzheimer’s Disease , 2016–2026(USD Million)
  • 5.3. Parkinson’s Disease
    • 5.3.1. Global Neurulogical Biomarkers Market by Parkinson’s Disease, 2016–2026(USD Million)
  • 5.4. Autism Spectrum Disorders
    • 5.4.1. Global Neurulogical Biomarkers Market by Autism Spectrum Disorders, 2016–2026(USD Million)
  • 5.5. Multiple Sclerosis
    • 5.5.1. Global Neurulogical Biomarkers Market by Multiple Sclerosis, 2016–2026(USD Million)
  • 5.6. Others
    • 5.6.1. Global Neurulogical Biomarkers Market by Others, 2016–2026(USD Million)

Chapter 6. Global Laser Cutting Machine Market– Type Analysis

  • 6.1. Global Neurulogical Biomarkers Market overview: By Type
    • 6.1.1. Global Neurulogical Biomarkers Market share, By Type, 2019 and 2026
  • 6.2. Proteomic
    • 6.2.1. Global Neurulogical Biomarkers Market By Proteomic, 2016–2026(USD Million)
  • 6.3. Genomic
    • 6.3.1. Global Neurulogical Biomarkers Market By Genomic, 2016–2026(USD Million)
  • 6.4. Imaging
    • 6.4.1. Global Neurulogical Biomarkers Market By Imaging, 2016–2026(USD Million)
  • 6.5. Metabulomic
    • 6.5.1. Global Neurulogical Biomarkers Market By Metabulomic, 2016–2026(USD Million)
  • 6.6. Others
    • 6.6.1. Global Neurulogical Biomarkers Market By Others, 2016–2026(USD Million)

Chapter 7. Global Laser Cutting Machine Market– End-User Analysis

  • 7.1. Global Neurulogical Biomarkers Market overview: By End-User
    • 7.1.1. Global Neurulogical Biomarkers Market share, By End-User, 2019 and 2026
  • 7.2. Independent Clinical Diagnostic Centers
    • 7.2.1. Global Neurulogical Biomarkers Market By Independent Clinical Diagnostic Centers, 2016–2026(USD Million)
  • 7.3. Hospital Laboratories
    • 7.3.1. Global Neurulogical Biomarkers Market By Hospital Laboratories, 2016–2026(USD Million)
  • 7.4. Research Organizations
    • 7.4.1. Global Neurulogical Biomarkers Market By Research Organizations, 2016–2026(USD Million)
  • 7.5. Others
    • 7.5.1. Global Neurulogical Biomarkers Market By Others, 2016–2026(USD Million)

Chapter 8. Company Profiles

  • 8.1. QIAGEN
    • 8.1.1. Overview
    • 8.1.2. Financials
    • 8.1.3. Product Portfulio
    • 8.1.4. Business Strategy
    • 8.1.5. Recent Developments
  • 8.2. Abbott
    • 8.2.1. Overview
    • 8.2.2. Financials
    • 8.2.3. Product Portfulio
    • 8.2.4. Business Strategy
    • 8.2.5. Recent Developments
  • 8.3. Thermo Fisher Scientific Inc.
    • 8.3.1. Overview
    • 8.3.2. Financials
    • 8.3.3. Product Portfulio
    • 8.3.4. Business Strategy
    • 8.3.5. Recent Developments
  • 8.4. Myriad RBM
    • 8.4.1. Overview
    • 8.4.2. Financials
    • 8.4.3. Product Portfulio
    • 8.4.4. Business Strategy
    • 8.4.5. Recent Developments
  • 8.5. Bio-Rad Laboratories, Inc.
    • 8.5.1. Overview
    • 8.5.2. Financials
    • 8.5.3. Product Portfulio
    • 8.5.4. Business Strategy
    • 8.5.5. Recent Development
  • 8.6. Athena Diagnostics
    • 8.6.1. Overview
    • 8.6.2. Financials
    • 8.6.3. Product Portfulio
    • 8.6.4. Business Strategy
    • 8.6.5. Recent Development
  • 8.7. Acumen Pharmaceuticals
    • 8.7.1. Overview
    • 8.7.2. Financials
    • 8.7.3. Product Portfulio
    • 8.7.4. Business Strategy
    • 8.7.5. Recent Development
  • 8.8. AbaStar MDx, Inc.
    • 8.8.1. Overview
    • 8.8.2. Financials
    • 8.8.3. Product Portfulio
    • 8.8.4. Business Strategy
    • 8.8.5. Recent Development
  • 8.9. Alseres Pharmaceuticals, Inc.
    • 8.9.1. Overview
    • 8.9.2. Financials
    • 8.9.3. Product Portfulio
    • 8.9.4. Business Strategy
    • 8.9.5. Recent Development
  • 8.10. BANYAN BIOMARKERS, INC.
    • 8.10.1. Overview
    • 8.10.2. Financials
    • 8.10.3. Product Portfulio
    • 8.10.4. Business Strategy
    • 8.10.5. Recent Development